Smallpox - Pipeline Review, H2 2016

Date: July 13, 2016
Pages: 84
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: SEE20BDAAD3EN
Leaflet:

Download PDF Leaflet

Smallpox - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Smallpox - Pipeline Review, H2 2016’, provides an overview of the Smallpox pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Smallpox
  • The report reviews pipeline therapeutics for Smallpox by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Smallpox therapeutics and enlists all their major and minor projects
  • The report assesses Smallpox therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Smallpox
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Smallpox
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Smallpox Overview
Therapeutics Development
Pipeline Products for Smallpox - Overview
Pipeline Products for Smallpox - Comparative Analysis
Smallpox - Therapeutics under Development by Companies
Smallpox - Therapeutics under Investigation by Universities/Institutes
Smallpox - Pipeline Products Glance
Late Stage Products
Early Stage Products
Smallpox - Products under Development by Companies
Smallpox - Products under Investigation by Universities/Institutes
Smallpox - Companies Involved in Therapeutics Development
Bavarian Nordic A/S
BioFactura, Inc.
CEL-SCI Corporation
Chimerix, Inc.
CJ HealthCare Corp.
EpiVax, Inc.
SIGA Technologies, Inc.
Takeda Pharmaceutical Company Limited
Tonix Pharmaceuticals Holding Corp.
Smallpox - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(plague + small pox) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

24A - DRUG PROFILE 36

Product Description
Mechanism Of Action
R&D Progress
brincidofovir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-40011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Smallpox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nilotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCV-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
small pox vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smallpox vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smallpox vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tecovirimat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIR-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Smallpox - Dormant Projects
Smallpox - Discontinued Products
Smallpox - Product Development Milestones
Featured News & Press Releases
Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government
Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA’s Tecovirimat Antiviral
Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene
Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox
Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million
May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine
Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery
Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million
Dec 23, 2014: Chimerix Provides Recap of 2014 Events
Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine
Sep 04, 2014: Bavarian Nordic Announces Exercise Of Contract Option By The U.S. Government For Continued Supply Of Imvamune Smallpox Vaccine
Sep 02, 2014: Chimerix and BARDA Announce Continued Partnership in the Development of Brincidofovir for Smallpox
Aug 26, 2014: Bavarian Nordic Receives Order from the Canadian Government to Supply IMVAMUNE Smallpox Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Smallpox, H2 2016
Number of Products under Development for Smallpox - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Smallpox - Pipeline by Bavarian Nordic A/S, H2 2016
Smallpox - Pipeline by BioFactura, Inc., H2 2016
Smallpox - Pipeline by CEL-SCI Corporation, H2 2016
Smallpox - Pipeline by Chimerix, Inc., H2 2016
Smallpox - Pipeline by CJ HealthCare Corp., H2 2016
Smallpox - Pipeline by EpiVax, Inc., H2 2016
Smallpox - Pipeline by SIGA Technologies, Inc., H2 2016
Smallpox - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Smallpox - Dormant Projects, H2 2016
Smallpox - Dormant Projects (Contd..1), H2 2016
Smallpox - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Smallpox, H2 2016
Number of Products under Development for Smallpox - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Smallpox - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Oncobiologics, Inc. - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 30 pages
Vaxdyn, S.L. - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 17 pages
Targovax AS - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 32 pages
Cholera - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 57 pages

Ask Your Question

Smallpox - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: